MedTrace Logo

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

NCT04682158 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2026-01-02

No results posted yet for this study

Summary

This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT, or definitive chemotherapy or chemotherapy-immunotherapy and will be considered separately as a single arm prospective cohort

Conditions

  • Esophageal Adenocarcinoma

Interventions

DRUG

Carboplatin

Given IV

RADIATION

3 Dimensional Conformal Radiation Therapy

Undergo 3D CRT

DRUG

Propranolol

Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks

RADIATION

Intensity Modulated Radiation Therapy

Undergo IMRT

DRUG

Paclitaxel

Given IV

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Anurag Singh, MD · Roswell Park Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2029-04-01
Completion
2029-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04682158 on ClinicalTrials.gov